Itraconazol bij ’red face’ tijdens dupilumabbehandeling

Translated title of the contribution: Itraconazole for 'red face' during treatment with dupilumab

Fleur de Beer*, I. Haeck, D. Bakker, L. Ariëns, J. van der Schaft, M. de Bruin-Weller, M. van Dijk

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

We present three patients who developed pronounced redness and scaling in the face, head and neck during treatment with dupilumab indicated for atopic dermatitis (AD). Clinically, these patients suffered from head-neck dermatitis, which is a subtype of AD. Histopathological results showed a remarkable neutrophilic dermatosis with an eczematous background and no characteristics of rosacea. We found an elevated serum level of specific IgE for Malassezia. Treatment with oral itraconazole showed a good clinical response.

Translated title of the contributionItraconazole for 'red face' during treatment with dupilumab
Original languageDutch
Pages (from-to)35-37
Number of pages3
JournalNederlands Tijdschrift voor Dermatologie en Venereologie
Volume29
Issue number4
Publication statusPublished - 1 Apr 2019

Keywords

  • Atopic dermatitis
  • Dupilumab
  • Head and neck dermatitis
  • Red face

Fingerprint

Dive into the research topics of 'Itraconazole for 'red face' during treatment with dupilumab'. Together they form a unique fingerprint.

Cite this